Clinical Research Directory

Inclusion Criteria: 1. Patients who provide written informed consent form (ICF) to participate in the study. 2. Male and female. 3. ≥ 18 years old. 4. Diagnosis of moderate or severe HS (Hurley stage and IHS4). 5. Patient who initiated treatment with secukinumab no longer than 4 weeks prior to written ICF. 6. Decision for secukinumab prescription was made by the attending physician according to the approved national label during routine clinical practice, regardless of study participation. Exclusion Criteria: 1. Any medical or psychological condition that may prevent the study participation, based on practitioners' decision-making. 2. Participation in an ongoing clinical trial. 3. Known or suspected severe hypersensitivity for secukinumab, formulation excipients, or injection device components (i.e., latex). 4. Clinically significant infection exacerbation, including active tuberculosis. 5. Patients with active inflammatory bowel disease (IBD). 6. Age \<18 years. 7. Pregnancy and breastfeeding. 8. Patients who received any vaccine within 4 weeks prior to secukinumab initiation.